KNOWLEDGE, DIAGNOSTIC PRACTICES, AND MANAGEMENT STRATEGIES OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) AMONG ENDOCRINOLOGISTS IN KAZAKHSTAN: A MULTICENTER CROSS-SECTIONAL STUDY
Keywords:
metabolic dysfunction-associated steatotic liver disease, type 2 diabetes mellitus, endocrinologists, surveyAbstract
Background. Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent in patients with type 2 diabetes mellitus (T2DM) and obesity. Assessing endocrinologists' clinical awareness, screening practices, and therapeutic strategies is essential to address gaps in multispecialty care.
Objective. This study evaluated endocrinologists' knowledge, diagnostic preferences, and management approaches to MASLD across Almaty, Almaty region, Zhambyl region, North Kazakhstan region, and Aktobe region.
Materials and methods. We conducted a multicenter, cross-sectional survey of 172 practicing endocrinologists from November 2025 to February 2026. A structured questionnaire assessed professional profiles, screening protocols, diagnostic modalities (ultrasonography, elastography with controlled attenuation parameter [CAP], liver biopsy), therapeutic interventions (lifestyle modifications, ursodeoxycholic acid [UDCA], e.g., Ursosan Forte, 500 mg), and clinical barriers. Data were analyzed in RStudio using descriptive statistics, Chi-squared, Fisher’s exact, and Kruskal-Wallis tests.
Results and discussion. The cohort of 172 physicians was predominantly female (90.7%) and held MD degrees (81.4%). Most respondents prioritized targeted screening for T2DM (91.9%) and obesity (88.4%), underscoring continued reliance on conventional risk-based approaches. Liver ultrasonography (94.2%) and liver enzymes (ALT: 73.3%, AST: 70.9%) were the primary diagnostic modalities, while advanced tools such as elastography with CAP (27.9%) and liver biopsy (19.8%) were used less frequently, highlighting a clear implementation gap in advanced non-invasive diagnostics. Lifestyle interventions remained central, with 89.5% recommending dietary modifications and 58.1% targeting 10% weight reduction. UDCA was prescribed by 74.4% of respondents primarily to improve liver enzymes (46.6%) and mitigate fibrosis (20.3%), though risk perceptions varied significantly across qualifications (p = 0.0222). Low patient adherence was the main clinical barrier (41.9%), further limiting implementation.
Conclusion: Endocrinologists actively prioritize metabolic risk screening and lifestyle management across the surveyed regions, but substantial gaps persist in advanced non-invasive diagnostics and pharmacological standardization, requiring unified guidelines and enhanced multidisciplinary collaboration.
References
u RR, Barb D, et al. Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care. 2025;48(7):1057–1082. https://doi.org/10.2337/dci24-0094
2. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol 2024;29(1):101133. https://doi.org/10.1016/j.aohep.2023.101133.
3. Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2022;7(9):851–61. https://doi.org/10.1016/S24681253(22)00165-0.
4. Harrison SA, Gawrieh S, Roberts K, et al. Prospective evaluation of the prevalence of nonalcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. J Hepatol 2021; 75:284–291
5. Harrison SA, Gawrieh S, Roberts K, et al. Prospective evaluation of the prevalence of nonalcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. J Hepatol 2021; 75:284–291
6. Greenhalgh J, Gooding K, Gibbons E, Dalkin S, Wright J, Valderas J, et al. How do patient reported outcome measures (PROMs) support clinician-patient communication and patient care? A realist synthesis. J Patient Rep Outcomes 2018;2(1):42. https://doi.org/10.1186/s41687-018-0061-6.
7. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and pre-vention. Nat Rev Gastroenterol Hepatol 2018;15:11–20.
8. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guid-ance from the American Association for the Study of Liver Dis-eases. Hepatology 2018;67:328–357.
9. Selvaraj EA, Mozes FE, Jayaswal ANA, et al. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. J Hepatol 2021;75:770-785.
10. Lin X, Mai M, He T, Huang H, Zhang P, Xia E, et al. Efficiency of ursodeoxycholic acid for the treatment of nonalcoholic steatohepatitis: a systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. (2022) 16:537–45. doi: 10.1080/17474124.2022.2083605
12. Matthias AT, Fernandopulle AN, Seneviratne SL. Survey on knowledge of non-alcoholic fatty liver disease (NAFLD) among doctors in Sri Lanka: a multicenter study. BMC Res Notes 2018;11:556.
13. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol 2021;75:659-689.
14. Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet 2021;397:2212-2224.
15. Stan SI, Biciuşcă V, Clenciu D, Mitrea A, Boldeanu MV, Durand P, et al. Te thera-peutic mechanisms and beneficial effects of ursodeoxycholic acid in the treatment of nonalcoholic fatty liver disease: a systematic revi ew. Med Pharm Rep. (2023) 97:12–25. doi: 10.15386/mpr-2629
16. Li B, Zhong P, Zhang X, Li C, Luan M, Chen Y, et al. CYP4A14-PPARα axis serves as a therapeutic target for ursodeoxycholic acid in ameliorating high-fat diet-induced MASLD. J Nutr Biochem. (2026) 147:110138. doi: 10.1016/j.jnutbio.2025.110138
17. Wang X, Liang G, Zhou Y, Ni B, Zhou X. Ameliorative effect and mechanism of ursodeoxycholic acid on hydrogen peroxide-induced hepatocyte injury. Sci Rep. (2024)14:4446. doi: 10.1038/s41598-024-55043-3
18. Hwang JS, Lai TH, Kim DR. Targeting lipophagy in liver diseases: impact on oxidative stress and steatohepatitis. Antioxidants. (2025) 14:908. doi: 10.3390/antiox14080908
